Imatinib mesylate induces clinical remission in rheumatoid arthritis

Joint Bone Spine

Volumn 77, Issue 4, 2010, Pages 372-373

  Pereira, Ivânio ^a   Fialho, Sonia ^a   Castro, Gláucio ^a   Zimmermann, Adriana ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Chronic myeloid leukaemia; Imatinib mesylate; Rheumatoid arthritis; Treatment

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; HYDROXYUREA; IMATINIB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; BONE MARROW BIOPSY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INJECTION SITE REACTION; LEG EDEMA; LETTER; LEUKOCYTOSIS; NAUSEA; PHILADELPHIA 1 CHROMOSOME; POLYARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; MIDDLE AGED; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME; BENZAMIDES;

EID: 77954625112     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.03.014     Document Type: Letter

References (10)

1. Almeida A., Castro I., Coutinho J., et al. Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia. Acta Med Port 2009, 22:537-544.
2. Koyama K., Hatsushika K., Ando T., et al. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 2007, 17:306-310.
3. Terabe F., Kitano M., Kawai M., et al. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. Mod Rheumatol 2009, 19:522-529.
4. Juurikivi A., Sandler C., Lindstedt K.A., et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 2005, 64:1126-1131.
5. Miyachi K., Ihara A., Hankins R.W., et al. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003, 22:329-332.
6. Eklund K.K., Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003, 35:362-367.
7. Ames P.R., Aye W.W., Beatty C., et al. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia. J Rheumatol 2008, 35:1682.
8. Eklund K.K., Lindstedt K., Sandler C., et al. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol 2008, 14:294-296.
9. Vernon M.R., Pearson L., Atallah E. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. J Clin Rheumatol 2009, 15:267.
10. Tebib J., Mariette X., Bourgeois P., et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 2009, 11:R95.